within Pharmacolibrary.Drugs.ATC.D;

model D06AX12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.07166666666666667,
    adminDuration  = 600,
    adminMass      = 0.5,
    adminCount     = 1,
    Vd             = 0.0161,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Amikacin is an aminoglycoside antibiotic used primarily for the treatment of severe bacterial infections caused by Gram-negative bacteria, including those resistant to other aminoglycosides. It is approved and commonly used today, mainly in hospital settings for serious infections such as sepsis, pneumonia, urinary tract infections, and intra-abdominal infections.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with normal renal function receiving intravenous infusion.</p><h4>References</h4><ol><li>Susanna E Medellín-Garibay, Melissa Romano-Aguilar, Alejandro Parada, David Suárez, Silvia Romano-Moreno, Emilia Barcia, Miguel Cervero, Benito García,Amikacin pharmacokinetics in elderly patients with severe infections.,European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,2022<a href='https://pubmed.ncbi.nlm.nih.gov/35618200/'>https://pubmed.ncbi.nlm.nih.gov/35618200/</a></li><li>Sílvia M Illamola, Catherine M Sherwin, J G Coen van Hasselt,Clinical Pharmacokinetics of Amikacin in Pediatric Patients: A Comprehensive Review of Population Pharmacokinetic Analyses.,Clinical pharmacokinetics,2018<a href='https://pubmed.ncbi.nlm.nih.gov/29572662/'>https://pubmed.ncbi.nlm.nih.gov/29572662/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D06AX12;
